NEW YORK, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for fiscal second quarter and six months ended December 31, 2023, and provided a business update.
“We are very pleased with our fiscal Q2 and six-month revenue results, reflecting our commitment to continuous growth of our customer base and global presence,” said, Harry Simeonidis, President and Chief Executive Officer at Intelligent Bio Solutions. “Our product sales have grown significantly, up 30% for cartridges and 91% for readers in the six months ending December 31, 2023, compared to the same period last year. This increase in volume has boosted our revenue growth to over 110% year over year, and we are seeing a growing awareness of our drug screening solution as we enter new markets and expand our global footprint. Last year our expansion into New Zealand marked a significant milestone, and we anticipate further expansion throughout the Asia-Pacific region this year. Our revenue growth numbers are indicative of an increasing need for an efficient drug screening solution that reduces risk, saves costs, and promotes productivity. We aim to sustain this rapid trajectory throughout 2024.”
Fiscal Second Quarter & Recent Highlights:
Fiscal Second Quarter Ended December 31, 2023, Financial Results
All amounts are expressed in U.S. dollars unless indicated otherwise. All authorized, issued, and outstanding stock and per share amounts reflect the 1-for-20 and 1-for-12 reverse stock split effected by the Company on February 9, 2023, and January 26, 2024, respectively, unless indicated otherwise.
Revenue from sales of goods increased by $0.40 million from $0.36 million to $0.76 million for the quarter ended December 31, 2023, compared to same period in 2022, representing a 114% increase. Revenue from sales of goods increased by $1.20 million from $0.36 million to $1.56 million for the six months ended December 31, 2023, compared to same period in 2022, representing a 337% increase. Increases in revenue are due to the acquisition of Intelligent Fingerprinting Ltd (“IFP”) in October 2022, and growth of the Company’s Asia Pacific business, Intelligent Bio Solutions (APAC) Pty Ltd, in addition to expansion into new regions and growth of the Company in existing markets and regions.
Net loss attributable to INBS increased by $2.76 million from $1.63 million to $4.39 million for the six months ended December 31, 2023, compared to the same period in 2022. This increase is primarily driven by combined results of operations after the acquisition of IFP offset by a recognition of fair value gain on revaluation of convertible notes and holdback Series C Preferred Stock of $1,793,091 during the same period in 2022.
On October 4, 2023, the Company raised approximately $4.38 million prior to deducting underwriting discounts and commissions and offering expenses via a registered underwritten public offering of the Company’s securities. Net proceeds to the Company after deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company, were approximately $3.79 million. The Company ended the quarter with cash and cash equivalents of approximately $1.12 million.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. Additionally, the Company's biosensor platform has the potential to test for up to 130 indications, ranging from glucose to immunological conditions and communicable diseases. The Company's current customer segments include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.
For more information, visit: http://www.ibs.inc/
Forward-Looking Statements:
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.'s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions' public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact:
Intelligent Bio Solutions Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
LinkedIn | Twitter
Media Contact:
Cheryl Billson
Comma Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
+44 (0)7791 720460
Intelligent Bio Solutions Inc.
Condensed Consolidated Balance Sheets
(Amounts in US$)
| December 31, 2023 (Unaudited) | June 30, 2023 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 1,119,004 | $ | 1,537,244 | ||||
| Accounts receivable, net | 262,834 | 293,861 | ||||||
| Inventories, net | 942,050 | 979,907 | ||||||
| Research and development tax incentive receivable | 289,167 | 498,758 | ||||||
| Other current assets | 331,601 | 552,791 | ||||||
| Total current assets | 2,944,656 | 3,862,561 | ||||||
| Property and equipment, net | 591,307 | 690,175 | ||||||
| Operating lease right-of-use assets | 432,728 | 546,475 | ||||||
| Intangible assets, net | 4,858,301 | 5,255,401 | ||||||
| TOTAL ASSETS | $ | 8,826,992 | $ | 10,354,612 | ||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable and accrued expenses | $ | 1,763,007 | $ | 2,610,028 | ||||
| Current portion of operating lease liabilities | 250,751 | 223,447 | ||||||
| Current portion of deferred grant income | 2,431,900 | 2,338,057 | ||||||
| Current employee benefit liabilities | 366,893 | 358,942 | ||||||
| Current portion of notes payable | 370,535 | 353,211 | ||||||
| Total current liabilities | 5,183,086 | 5,883,685 | ||||||
| Employee benefit liabilities, less current portion | 29,993 | 24,902 | ||||||
| Operating lease liabilities, less current portion | 228,710 | 356,165 | ||||||
| Notes payable, less current portion | 230,969 | 402,862 | ||||||
| Total liabilities | 5,672,758 | 6,667,614 | ||||||
| Commitments and contingencies | ||||||||
| Shareholders’ equity: | ||||||||
| Common stock, $0.01 par value, 100,000,000 shares authorized, 1,476,042 and 194,200 shares issued and outstanding at December 31, 2023 and June 30, 2023, respectively* | 14,760 | 1,942 | ||||||
| Treasury stock, at cost, 116 shares as of December 31, 2023 and June 30, 2023, respectively* | (1 | ) | (1 | ) | ||||
| Additional paid-in capital | 49,986,220 | 46,180,112 | ||||||
| Accumulated deficit | (46,202,418 | ) | (41,807,573 | ) | ||||
| Accumulated other comprehensive loss | (518,379 | ) | (575,496 | ) | ||||
| Total consolidated Intelligent Bio Solutions Inc. equity | 3,280,182 | 3,798,984 | ||||||
| Non-controlling interest | (125,948 | ) | (111,986 | ) | ||||
| Total shareholders’ equity | 3,154,234 | 3,686,998 | ||||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $ | 8,826,992 | $ | 10,354,612 | ||||
| * | Common stock and per share amount have been retroactively adjusted to reflect the decreased number of shares resulting from a 1-for-12 reverse stock split effected on January 26, 2024, and a 1-for-20 reverse stock split effected on February 9, 2023, throughout the condensed consolidated financial statement unless otherwise stated. |
Intelligent Bio Solutions Inc.
Condensed Consolidated Statements of Operations and Other Comprehensive Loss*
(Unaudited)
(Amounts in US$)
| Three Months Ended December 31, | Six Months Ended December 31, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Revenue | $ | 764,063 | $ | 356,679 | $ | 1,560,157 | $ | 356,679 | ||||||||
| Cost of revenue (exclusive of amortization shown separately below) | (564,815 | ) | (112,635 | ) | (1,128,578 | ) | (112,635 | ) | ||||||||
| Gross profit | 199,248 | 244,044 | 431,579 | 244,044 | ||||||||||||
| Other income: | ||||||||||||||||
| Government support income | 153,204 | 269,625 | 263,075 | 580,945 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Selling, general and administrative expenses | (1,705,044 | ) | (2,245,289 | ) | (4,162,104 | ) | (3,695,707 | ) | ||||||||
| Development and regulatory approval expenses | (348,452 | ) | (1,191 | ) | (452,399 | ) | (80,465 | ) | ||||||||
| Depreciation and amortization | (290,313 | ) | (398,156 | ) | (597,873 | ) | (398,156 | ) | ||||||||
| Total operating expenses | (2,343,809 | ) | (2,644,636 | ) | (5,212,376 | ) | (4,174,328 | ) | ||||||||
| Loss from operations | (1,991,357 | ) | (2,130,967 | ) | (4,517,722 | ) | (3,349,339 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest expense | (32,468 | ) | (76,767 | ) | (69,916 | ) | (77,832 | ) | ||||||||
| Realized foreign exchange loss | (555 | ) | (13,901 | ) | (555 | ) | (16,148 | ) | ||||||||
| Fair value gain on revaluation of financial instrument | 44,488 | 1,793,091 | 175,738 | 1,793,091 | ||||||||||||
| Interest income | 3,509 | 1,473 | 3,648 | 9,079 | ||||||||||||
| Total other income | 14,974 | 1,703,896 | 108,915 | 1,708,190 | ||||||||||||
| Net loss | (1,976,383 | ) | (427,071 | ) | (4,408,807 | ) | (1,641,149 | ) | ||||||||
| Net loss attributable to non-controlling interest | (6,742 | ) | (6,471 | ) | (13,962 | ) | (12,256 | ) | ||||||||
| Net loss attributable to Intelligent Bio Solutions Inc. | $ | (1,969,641 | ) | $ | (420,600 | ) | $ | (4,394,845 | ) | $ | (1,628,893 | ) | ||||
| Other comprehensive income, net of tax: | ||||||||||||||||
| Foreign currency translation gain | $ | 75,133 | $ | 361,597 | $ | 57,117 | $ | 226,038 | ||||||||
| Total other comprehensive income | 75,133 | 361,597 | 57,117 | 226,038 | ||||||||||||
| Comprehensive loss | (1,901,250 | ) | (65,474 | ) | (4,351,690 | ) | (1,415,111 | ) | ||||||||
| Comprehensive loss attributable to non-controlling interest | (6,742 | ) | (6,471 | ) | (13,962 | ) | (12,256 | ) | ||||||||
| Comprehensive loss attributable to Intelligent Bio Solutions Inc. | $ | (1,894,508 | ) | $ | (59,003 | ) | $ | (4,337,728 | ) | $ | (1,402,855 | ) | ||||
| Net loss per share, basic and diluted* | $ | (2.07 | ) | $ | (5.56 | ) | $ | (7.68 | ) | $ | (23.65 | ) | ||||
| Weighted average shares outstanding, basic and diluted* | 949,660 | 75,690 | 571,930 | 68,866 | ||||||||||||
| * | Common stock and per share amount have been retroactively adjusted to reflect the decreased number of shares resulting from a 1-for-12 reverse stock split effected on January 26, 2024, and a 1-for-20 reverse stock split effected on February 9, 2023, throughout the condensed consolidated financial statement unless otherwise stated. |
| Last Trade: | US$1.48 |
| Daily Change: | -0.04 -2.63 |
| Daily Volume: | 95,468 |
| Market Cap: | US$4.620M |
November 13, 2024 November 07, 2024 October 29, 2024 October 16, 2024 October 01, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
